Lotta Ljungqvist
Non-Executive Director, Abzena plc
Pharma
Abzena S.L
Spain
Biography
Lotta Ljungqvist was appointed President & CEO of GE for the Nordic Region in 2017. She is primarily responsible for GE’s overall growth in the region and acts as the key interface to GE for governmental and corporate relations. Dr. Ljungqvist is also CEO the BioProcess Innovation Center in Uppsala, a private public partnership to grow industrialization of BioProcess biology and technology innovation. She is also on the board of Vinnova, Sweden Bio, AmCham Sweden and Atlas Antibodies AB. Dr Ljungqvist was previously Global Head of BioProcess R&D in GEHC Life Science during 2008-1016 responsible for development of new equipment and consumables for the BioPharma Industry. During 2007/2008 she was CEO of IMEA AB, a biotech company dedicated to develop Biopharmaceuticals. Prior to that, Dr Ljungqvist headed a Biopharmaceutical Contract Manufacturing Organization in Biovitrum during 2001-2007. From 1990-2001 she held several project management positions with Pharmacia Corp & Pharmacia & Upjohn including Project Director for the development of a biopharmaceutical. Lotta received her PhD 1990 in Biochemistry and a M.Sc. in Biochemical Engineering in 1985 from the Royal Institute of Technology in Stockholm.
Research Interest
industrialization of BioProcess biology and technology innovation.
